Here, we present a case of successful treatment with ixekizumab, a humanized monoclonal anti-IL-17A antibody, in an atypical juvenile PRP (type V) patient with a novel variant of CARD14 mutation. The gene discussed is IL17A; the disease is familial pityriasis rubra pilaris.